ALISO
VIEJO, Calif., Oct. 21,
2024 /PRNewswire/ -- Okami Medical today announced
the closing of a $32.5M financing led
by new investor Vensana Capital and joined by existing investors
including U.S. Venture Partners, members of Okami's board of
directors, and other medical device industry veterans. Okami was
launched by medical device incubator Inceptus Medical, whose
principals previously founded other category-defining vascular
companies including Inari Medical, Sequent Medical, and
MicroVention.
The financing provides Okami with capital to accelerate
development and commercialization of its innovative catheter-based
technologies for peripheral vascular occlusion. To-date, Okami has
developed the LOBO® Vascular Occlusion System and the
SENDERO® Microcatheter. The LOBO Vascular Occlusion
System is uniquely designed to provide interventional
physicians with a single-device, one-and-done solution for the
occlusion of a wide range of peripheral arterial targets without
the need for multiple embolic devices. The SENDERO
Microcatheter is designed for smooth delivery of interventional
devices, while providing optimal trackability through tortuous
peripheral vessels.
"We are honored to have the support of Vensana and our existing
investors to advance these important technologies and deliver them
to patients," said Rhonda Robb,
President and CEO of Okami. "We are also grateful for the support
and contributions of our employees and physician partners as we
work tirelessly to build the market leader in vascular
occlusion."
"LOBO and SENDERO address many of the shortcomings of
traditional coils and vascular plugs. Designed for predictable,
rapid, and durable occlusion, the platform represents a meaningful
step forward in the treatment of vascular disease," commented
Mike Kramer and Kirk Nielsen of Vensana Capital. "We
are excited to work alongside the Okami team to bring these and
other important technologies to patients and to partner with
longtime colleagues and co-investors to build another
market-leading vascular company."
The LOBO (LOw-profile Braided Occluder) system enables treatment
of vessel ranges from 1.5mm to 9.0mm with just four sizes and
combines a patented design with
proprietary HDBRAID® technology to create a
highly occlusive pore structure that substantially reduces blood
flow and accelerates vessel closure. The advanced technology
platform enables the fast and efficient closure of blood vessels
throughout the body for the successful treatment of a diverse set
of conditions.
The SENDERO Microcatheter is 510(k) cleared by the U.S. FDA and
is purpose-built and optimized for the delivery of LOBO-3 and
LOBO-5. Its design incorporates a hydrophilic coating, stainless
steel braid, and radiopaque marker band to optimize trackability
and enable precise placement of interventional devices, while a
lubricious PTFE inner liner allows for low-friction delivery of
interventional devices.
About Okami Medical
Okami Medical, Inc. is a privately held medical device company with
a mission to address the evolving needs of patients and physicians
through the development of innovative, versatile, and intuitive
devices for the occlusion of peripheral vessels. The company was
created in 2017 by Inceptus Medical, a medical device incubator.
The Inceptus team has a track record of creating innovative and
successful companies including Inari Medical (NASDAQ: NARI),
Sequent Medical (acquired by Terumo in 2016) and MicroVention
(acquired by Terumo in 2006). Okami is backed by members of the
board of directors, Vensana Capital, U.S. Venture Partners (USVP),
and medical device industry veterans. For more information, please
visit www.okamimedical.com.
About Vensana Capital
Vensana Capital is a venture
capital and growth equity investment firm dedicated to partnering
with entrepreneurs who seek to transform healthcare with
breakthrough innovations in medical technology. Launched in 2019,
Vensana manages $550M in capital and
is actively investing in development and commercial stage companies
across the medtech sector, including medical devices, diagnostics
and data science, digital health, life science tools, and
tech-enabled services. Vensana's investment team has a history of
successfully partnering with management teams behind
industry-leading companies including Artelon, Cameron Health,
CardiAQ, Cartiva, CV Ingenuity, Epix Therapeutics, Inari Medical,
Intact Vascular, Lutonix, Neuwave Medical, Personal Genome
Diagnostics, Relievant Medsystems, Sequent Medical, Topera,
Ulthera, Veran Medical Technologies, Vertiflex, and Vesper
Medical.
About U.S. Venture Partners
U.S. Venture Partners (USVP) is a leading Silicon Valley venture
capital firm, partnering with entrepreneurs to transform their
ideas into world-changing companies. USVP has invested in over 500
companies spanning four decades, including: Box, Cato Networks,
Edgewise, Epsagon, Happy Returns, HotelTonight, Human Interest,
Imperva, Inari Medical, Inspire Medical Systems, Intersect ENT,
Kenna, Medigate, MeetMe, Omada Health, Pluto TV, Primary,
Smartling, Supplyframe, Standard Bariatrics, ThreatMetrix, Trunk
Club, Trusteer and Yammer. USVP focuses on early-stage start-ups
that transform cybersecurity, enterprise software, consumer and
healthcare. The USVP team consists of former entrepreneurs,
technologists, corporate executives, and financial professionals
who assist with strategy, scaling, team building, product
development, and business development. USVP is based in
Menlo Park, California.
Source:
Okami Medical, Inc.
949-446-9710
info@okamimedical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/okami-medical-announces-closing-of-32-5m-financing-302280586.html
SOURCE Okami Medical Inc.